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Abstract
Background p53 is a tumor suppressor that is frequently
mutated in human cancers. Although alterations in p53 are
common in breast cancer, few studies have specifically
investigated TP53 mutations in the breast cancer subtype
invasive lobular carcinoma (ILC). Recently reported condi-
tional mouse models have indicated that functional p53
inactivation may play a role in ILC development and pro-
gression. Since reports on the detection of TP53 mutations
in the relatively favorable classic and more aggressive pleo-
morphic variants of ILC (PILC) are rare and ambiguous, we
performed a comprehensive analysis to determine the muta-
tion status of TP53 in these breast cancer subtypes.
Methods To increase our understanding of p53-mediated
pathways and the roles they may play in the etiology of
classic ILC and PILC, we investigated TP53 mutations
and p53 accumulation in a cohort of 22 cases of classic
and 19 cases of PILC by direct DNA sequencing and
immunohistochemistry.
Results We observed 11 potentially pathogenic TP53 muta-
tions,ofwhichthree weredetectedinclassic ILC (13.6%) and
8i nP I L C( 4 2 . 1 % ;p=0.04). While p53 protein accumulation
was not significantly different between classic and pleomor-
phic ILC, mutations that affected structure and protein func-
tion were significantly associated with p53 protein levels.
Conclusion TP53 mutations occur more frequently in PILC
than classic ILC.
Keywords Breastcancer.p53.Mutation.Invasive lobular
breastcancer.Classic.Pleomorphic
1 Introduction
The tumor suppressor p53 was first described in 1979 as a key
cell cycle regulator. Upon cellular stress, the p53 signaling
pathway turns on the expression of genes including inhibitors
of cell cycle, DNA repair, and apoptosis [1, 2]. Inactivating
alterations in the p53 gene are commonly observed in human
cancers, resulting in suppression of the regulatory functions of
p53 which contributes to transformation of cells. Mutations in
p53 are observed in breast cancer, however with a lower
frequency (~ 20%) compared to other solid tumors [2]. Al-
thoughithasbeenwellestablishedthatp53mutationscorrelate
with high grade and triple negativity [3, 4], the p53 mutation
spectrum across the various different histological types of
breast cancer has not been well defined.
Invasive lobular cancer (ILC) accounts for approximately
15% of breast cancers [5]. Based on their molecular profile,
most ILC belong to the luminal–type breast cancers. Within
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composed of small regular cells with frequently intracytoplas-
mic vacuoles, small nuclei and a typical trabecular infiltration
pattern with dissociated cells or forming single files, often in
targetoid patterns around uninvolved ducts and with low
mitotic rate; 2) the better demarcated alveolar type exhibiting
smallroundaggregatesof20ormorecellswithtypicallobular
cytology;3)thealsobetterdemarcatedsolidvariantconsisting
of more solid sheets of cells with little intervening stroma,
more mitoses and often some more atypia; 4)the pleomorphic
variant that exhibits the growth pattern of classical lobular
carcinoma throughout but with polygonal, eccentric pleomor-
phic nuclei and more frequent mitoses [6]. The pleomorphic
variant of ILC (PILC) accounts for less than 1% of all breast
carcinomas and not more than 10% of all ILC [7]. It has a
poorer prognosis compared to classic ILC [5, 8]. Several
studies have addressed the molecular and histological aspects
of PILC as a separate entity. Immunohistochemical analyses
demonstrated that PILCs frequently express estrogen (ER)
and progesterone (PR) receptors and are mostly E-cadherin
negative, Her2 positive and occasionally p53 positive [8–12].
Although expression of gross cystic disease fluid protein
(GDCFP) has been used to facilitate differential diagnosis
between classic ILC and PILC, reliability is variable
[11–14]. Little is known about p53 mutation status in PILC.
In view of the higher nuclear grade and poorer prognosis, one
would expect a higher frequency of p53 mutation in PILC.
Interestingly, conditional knock-out mouse models have indi-
cated that functional inactivation of p53 may play a role in
carcinogenesisandprogressionofmousePILC[15,16].Inthe
present study, we have investigated the p53 mutation status in
a series of 41 ILC cases including 22 classic and 19 pleomor-
phic subtypes to advance current knowledge on these variants
of ILC.
2 Materials and methods
2.1 Patients
Archival material from 41 breast cancer patients with lobu-
lar carcinoma was collected from the Pathology departments
of the University Medical Center Utrecht, Utrecht, The
Netherlands and Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands, and the Institute of
Pathology, Paderborn, Germany. ILC and PILC were iden-
tified on Hematoxylin and Eosin (H&E) stained reference
slides from formaldehyde-fixed paraffin embedded breast
cancer tissue blocks of 41 cases by an experienced pathol-
ogist (PJvD), considering cases with nuclear atypia score 3
as PILC. Use of anonymous or coded left over material for
scientific purposes is a part of the standard treatment con-
tract with patients in our hospitals [17].
2.2 DNA extraction
After de-paraffinization of the slides by standard methods, the
relevant area from each slide (as identified on corresponding
H&E stained sections) was scraped off with a scalpel and
suspended in lysis buffer (Tris/HCl buffer pH 8.0 with
Tween). Then, proteinase K was added and the samples were
incubated for 1 h at 56°C. After that, samples were incubated
at 95°C for 10 min to inactivate proteinase K.
2.3 Sequencing and mutation analysis
For the detection of mutations, genomic DNA was amplified
with primers flanking exons 4, 5, 6, 7, 8 and 9 of the TP53
gene (Table 1). The PCR conditions were set up as follows;
initial denaturation at 94°C for 3 min, 35 cycles at 94°C for
1 min (denaturation), 60°C for 30 s (annealing) and 72°C for
45 s (extension), followed by a final extension at 72°C for
5 min. Then, PCR products were sequenced in both sense and
antisense directions using the BigDye Terminator v1.1 se-
quencing kit on ABI 3130 (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instructions. The
sequences were analyzed using Mutation Surveyor software
(SoftGenetics,LLC., State College, PA, USA).
2.4 Immunohistochemistry
Four μm thick sections were cut from the paraffin blocks
and transferred to Superfrost + slides (Menzel and Glaeser,
Braunschweig, Germany). Citrate buffer was used for anti-
gen retrieval. Immunohistochemistry was then performed
Table 1 Summary of primer sequences
Exon Sequence
4.1 FW 5′ CTG GTC CTC TGA CTG CTC 3′
4.1 RV 5′ GAC AGA AGA TGA CAG GGG 3′
4.2 FW 5′ AGC TCC CAG AAT GCC AGA G 3′
4.2 RV 5′ TGA AGT CTC ATG GAA GCC 3′
5.1 FW 5′ CCG TGT TCC AGT TGC TTT ATC 3′
5.1 RV 5′ GCT GTG ACT GCT TGT AGA TG 3′
5.2 FWa 5′ TCA ACA AGATGT TTT GCC AAC TGG 3′
5.2 FWb 5′ ACA AGATGT TTT GCC AAC TG 3′
5.2 RVint 5′ GAG CAA TCA GTG AGG AAT CAG 3′
6F W 5 ′ TCC CCA GGC CTC TGA TTC 3′
6R V 5 ′ CTG ACA ACC ACC CTT AAC C 3′
7F W 5 ′ CTT GCC ACA GGT CTC CCC AA 3′
7R V 5 ′ GCG GCA AGC AGA GGC TGG 3′
8F W 5 ′ CCT TAC TGC CTC TTG CTT C 3′
8R V 5 ′ TAA CTG CAC CCT TGG TCT C 3′
9F W 5 ′ GTT ATG CCT CAG ATT CAC T 3′
9R V 5 ′ TGA GTG TTA GAC TGG AAA C 3′
112 C. Ercan et al.with a mouse monoclonal p53 antibody, clone BP53-12-1,
10 mg/mL stock, (MU 195-UC, BioGenex, San Ramon,
CA, USA; 1:100) on an automated immunostainer (Bond-
MaX, Leica, Bannockburn, IL). Slides were counterstained
with hematoxylin, dehydrated, and cover-slipped. Through-
out the immunohistochemical analysis, negative controls
were obtained by omitting the primary antibody and staining
of a colon cancer tissue with a verified p53 mutation was
used as a positive control. Scoring of the stained nuclei was
performed by an experienced pathologist (PJvD). p53 was
regarded as accumulated when ≥5% of nuclei were stained.
p53 was regarded as wild-type when approximately 1% of
nuclei showed expression.
2.5 Statistical analysis
Chi-Squared test, or, when appropriate, Fischer’s Exact test
was applied to compare frequencies between groups with the
SPSS 15.0softwarepackage (IBM), regarding p-values <0.05
as significant.
3 Results
We identified the pleomorphic ILC variant using H&E
staining, based on a classical trabecular ILC growth pattern,
but with polygonal eccentric pleomorphic nuclei and more
frequent mitoses (cases with nuclear atypia score 3). We
have not observed a significant increase in HER2 expression
in PILC when comparing with classical ILC in our samples
(data not shown).
Therationalebehindourinvestigationofp53inclassicILC
and PILC is gaining a new insight into distinctive gene alter-
ations which give rise to these two different subtypes of ILC.
3.1 p53 mutations
To investigate the incidence of TP53 mutations in clas-
sic ILC and PILC, we performed PCR on exons 4–9
(conserved midregion) of TP53 for 41 ILC cases (22
classic ILC and 19 PILC). Direct DNA sequencing was
subsequently performed on PCR products. Overall, we
detected 11 mutations (of which 1 novel and 10 previ-
ously reported) and 2 validated polymorphisms in 41
ILC cases (Tables 2 and 3). One out of 11 mutations
was located in an intron and 10 mutations were located
in coding regions. Using the freely available IARC
TP53 database, we have scrutinized the following; the
functions of the domains in which the mutated residues
are located, the known functions of the wild-type resi-
dues, the effect of the mutations, the predicted effect on
splicing, functional predictions based on the structure change
and previously reported tumor sites (Table 2)[ 18, 19]. This
data summarized in Table 2 allowed us to predict the patho-
genicityoftheobservedmutations.Weconcludethatallofthe
11 mutations found could potentially be pathogenic based on
the mentioned criteria above.
Next, we evaluated the distribution of these potential-
ly pathogenic mutations over classic and pleomorphic
ILC variants. Eight of the 19 PILC cases (42.1%)
exhibited a potentially pathogenic mutation which is
significantly more often when compared to the percent-
age of potentially pathogenic mutations found in classic
ILC cases (3 mutations (missense) observed in 22 clas-
sic ILC cases (13.6%; p≤0.05)) (Table 4). We have also
observed two previously reported and validated poly-
morphisms among our samples. These were distributed
similarly over the classic and pleomorphic ILC variants
(Table 3).
3.2 p53 expression and accumulation
p53 immunostaining was performed to investigate the
correlation of mutational status and effects on protein
expression (Fig. 1). Immunohistochemistry scores and
mutation data of each case are summarized in Table 2.
We observed a variation in the immunohistochemistry
scores of p53 in both pleomorphic and classic cases. In
normal breast tissue, p53 staining is observed in a small
percentage (approximately 1%) of the cells. Therefore, 5%
positivity was chosen as a value to distinguish normal,
wild-type p53 expression and mutated p53 overexpression.
Overall, 9/41 cases (21.9%) showed p53 accumulation,
while 6 cases showed absence of expression. Of these
15 cases, 6 were ILC and 9 PILC (p00.157). In conclu-
sion, p53 accumulation was not associated exclusively
with a specific ILC variant.
3.3 Correlation of p53 accumulation and mutation
Because a large body of literature has shown that p53
accumulation can be caused by mutations in TP53,w e
set out to investigate the correlation between p53 accu-
mulation and mutation. In total, 5 out of 9 cases that
showed p53 accumulation based on immunohistochemis-
try harbored mutations (Table 5). Interestingly, we
detected potential pathogenic mutations in 4 of the 32
cases without p53 accumulation (wild-type staining + 0%
staining) (p00.01), while 1 of 6 cases showed a patho-
genic mutation in the absence of p53 staining (0% stain-
ing). However, the 5 remaining cases with 0% staining
had one of the two validated polymorphisms (Number 2
in Table 3). In summary, we observed a significant
correlation of p53 accumulation with potentially patho-
genic mutations (Table 5).
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Pleomorphic ILC was first described in 1982 as a variant of
infiltrating lobular carcinoma [20]. Even though the morphol-
ogy of PILC with high nuclear atypia is distinctive, its feature
of high frequency of multicentrity and bilaterality seem to be
similar to the classic ILC [21]. The report of Weidner and
Semple [9] is one of several reports demonstrating the aggres-
sive clinical behavior and poorer prognosis of patients with
PILC in comparison to patients with ILC [9]. Therefore,
despite the similarities between them, the question mark on
the genetic pathways through which each variant evolves still
remains. The TP53 tumor suppressor gene has been an inter-
esting target to investigate in invasive breast cancer since it is
very frequently altered in other human cancers [22]. Many
research groups have investigated the distribution of p53
mutations and its correlation with immunohistochemistry in
invasive carcinomas [23–27] but data focusing on different
variantsofILCarelimited.Thereforeouraimwastostudythe
mutational status of p53 in classic and pleomorphic ILC to
gain a better understanding of the molecular changes occur-
ring in this gene, which possibly contribute to the develop-
ment of these subtypes and the potential of it as a tool to
differentially diagnose ILC versus PILC.
In the present work, we studied 41 ILC cases for p53
mutations and accumulation in relation to the classic and
pleomorphic variants. Eleven mutations were detected in 41
cases studied (26%) which is in line with the literature which
states that the overall frequency of p53 mutations in breast
cancer is approximately 20% [28]. Almost all the observed
mutationslocateinthehighlyconservedDNA-bindingdomain
of the protein [18] (Table 2). Interestingly, our mutation anal-
ysis reveals that PILC is associated with a higher frequency
(42.1%) of potentially pathogenic p53 mutations compared to
ILC (13.6%). Even though some of these potentially patho-
genic mutations (4 out of 11 mutations) do not result in an
amino acid change, they have been reported before in different
solid tumors including breast cancer [18]. These silent muta-
tions are of particular interest. It has already been known for
decades that non-transforming mutations can affect the protein
production and therefore the function by interfering with var-
ious phases of transcription and translation [29]. Examples to
possible scenarios are: i) interference with the editing of a gene
transcript if silent mutations occur in codons that contain
splicing enhancers responsible for the proper removal of
introns, or ii) interference with the stability of mRNA by
preventing correct folding; thus affecting the speed of transla-
tion of the protein as well as the degradation of the mRNA.
Strikingly,Lamolleetal.recentlyshowedthatallreportednon-
transforming mutations of p53 which are documented in p53
somatic mutation database are preferentially located in con-
served amino acid positions, which may depict their impor-
tance [30]. The majority of these mutations were found as
single mutations, so never associated with other mutations in
p53 gene, and they tended to be located inside suspected
splicing enhancers. Interestingly, silent mutations observed in
our study also exist as single mutations and locate either in an
exposed residue of the DNA-binding domain or cause a pre-
dicted change in splicing. Moreover, silent mutations in p53
may also lead to a functional response by interfering with
binding to MDM2. In this scenario, single silent point muta-
tions in p53 mRNA can disrupt its binding to MDM2 resulting
in aberrant p53 synthesis and degradation [31]. This failure in
bindingis shown to reduce p53activity, thereby supportingthe
notion that silent p53 mutations can affect p53 function.
Table 3 p53 mutation analysis results of Classic and Pleomorphic Lobular Breast Cancer [18] (Version of the database; R15, November 2010)
Number Location Genomic
description
Aminoacid
change
Domain
function
b
Effect
c Predicted effect
on splicing
d
Observed in
1 Exon4 g.11339G>A 36P>P Transactivation Silent NA 3 PILC and 3 ILC cases
2 Exon4 g.11446C>G
a 72P>R SH3-like/Pro-rich Missense New Site 11 PILC and 18 ILC cases
aSeveral studies showed its association with breast cancer in different populations
bDomain Function; Function of the domain in which the mutated residue is located
cEffect; Effect of the mutation. The terms occurring in this column are: missense (change of one amino-acid) and silent (no change in the protein
sequence)
dPredicted Effect on Splicing; This is the predicted effect of the mutation on splicing based on two splicing prediction tools NNSPLICE0.9 and
HSF V2.3. No significant change: no change in the wild type splice motif. New site: the mutation created a splice motif which is not present in the
wt sequence. Site broken: the mutation removed a splice motif that was identified in the wt sequence. (NA 0 Not available)
Table 4 Correlation of potentially pathogenic p53 mutations with
classic and pleomorphic invasive lobular carcinomas
Potentially pathogenic p53 mutations
+ −
Classic ILC 3 (13.6%) 19 (86.4%) Total 22
PILC 8 (42.1%) 11 (57.9%) Total 19
p<0.05 *
p53 Mutations in Classic and Pleomorphic ILC 115Therefore, we think that our observation is noteworthy and in
thelightofrecentdiscoveriesinthisfield,assumptionsonnon-
transforming mutations should be made carefully. We have
also observed two previously reported and validated polymor-
phisms in a high number of our cases with no significant
preference for either ILC variant. Of note is the fact that these
polymorphisms were shown to be related with cancer
susceptibility [18]. Especially the amino acid change
72P> R(Table3) has beenshown tobeassociatedwithbreast
cancer susceptibility [32–36].
The observation of this significantly increased frequency
of pathogenic mutations in PILC -more than half of which
do probably give rise to a non-functional protein based on
predictions of computer models and for some based on
literature (Table 2)- is also in line with mouse studies in
which stochastic somatic inactivation of p53 and E-cadherin
in the mammary gland induced the development of mouse
PILC [16]. For some of the observed potentially pathogenic
mutations, predictions on function of the protein were not
available. However, it would not be unexpected if there
were activating mutations among them since mutant p53
protein can also have a distinct function in cancer such as
promoting invasion and metastases [37].
Another observation in this study was the significant
correlation between p53 accumulation and transforming
pathogenic mutations independent of any ILC variant. The
positive correlation between p53 accumulation and muta-
tions were made by other groups [4, 38–40] although not by
all [41, 42]. It is apparent that the correlation between
accumulation and mutations also depends on the influence
of the mutation on the half-life of the protein. Most mutant
forms of p53 have a longer cellular life and are therefore
recognized by antibodies while others are not. This can
explain our differential observation of p53 accumulation
when all mutations are counted. A mutation might cause a
misfolding of the protein structure (such as the above men-
tioned silent mutations resting in splicing enhancers or play-
ing a role in mRNA stability) or a truncation that affects the
c)  d)
a)  b)
100µm
100µm
100µm
100µm
Fig. 1 p53 expression in PILC.
a-d. Representative examples
of p53 expression of PILC
cases (a) wild-type; 1% positive
nuclei (b) no expression and
absence of mutations (c)
‘g.12368C>A’ mutation result-
ing in 100% p53 overexpres-
sion (d) ‘g.13440C>T’
mutation occurring in an intron
site and resulting in absence of
p53 expression
Table 5 Correlation between p53 mutations that give rise to a non-
functional structure and p53 accumulation
Mutations causing a predicted defect in p53
structure
− +
p53
Accumulation
− 32 0
+4 5
p≤0.001*
116 C. Ercan et al.epitope that is recognized by the antibody. We have also
observed a case with p53 accumulation but no mutations.
An explanation for this may be the possibility of mutations
that are located outside of the investigated exons. Interest-
ingly, a high percentage of p53-negative cases showed a
polymorphism in residue 72, a mutation that has been im-
plicated in enhanced targeting for degradation [43] provid-
ing a possible explanation for the p53 negativity in these
cases. However, based on published data and our results, we
can conclude that p53 immunostaining does not always
reflect the genetic alteration and vice versa; the existence
of a mutation does not always lead to p53 accumulation or
complete lack of expression.
In conclusion, the clinically more aggressive pleomor-
phic variant of ILC bears a significantly higher frequency of
p53 mutations compared to the classic variant, Moreover,
since inactivation of p53 and E-cadherin in mice leads to the
development of PILC, we envisage that p53 mutations may
play a role in carcinogenesis of PILC.
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